	US 11,857,561 B2
	Methods for the use of 5′-adenosine diphosphate ribose (ADPR)
Robert Shalwitz, Bexley, OH (US)
Assigned to Invirsa, Inc., Columbus, OH (US)
Filed by Invirsa, Inc., Columbus, OH (US)
Filed on Aug. 3, 2021, as Appl. No. 17/392,578.
Application 17/392,578 is a division of application No. 15/999,269, granted, now 11,110,112, previously published as PCT/US2017/018253, filed on Feb. 17, 2017.
Claims priority of provisional application 62/428,721, filed on Dec. 1, 2016.
Claims priority of provisional application 62/296,665, filed on Feb. 18, 2016.
Prior Publication US 2022/0054522 A1, Feb. 24, 2022
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 31/7076 (2006.01); A61P 27/02 (2006.01); A61P 35/00 (2006.01); A61K 9/00 (2006.01); A61K 31/522 (2006.01); A61K 31/675 (2006.01); A61K 33/24 (2019.01); A61K 33/30 (2006.01); A61K 33/34 (2006.01); C07H 19/207 (2006.01)

CPC A61K 31/7076 (2013.01) [A61K 9/0014 (2013.01); A61K 31/522 (2013.01); A61K 31/675 (2013.01); A61K 33/24 (2013.01); A61K 33/30 (2013.01); A61K 33/34 (2013.01); A61P 27/02 (2018.01); A61P 35/00 (2018.01); C07H 19/207 (2013.01)]

5 Claims

1. A pharmaceutical composition suitable for topical administration to the eye, respiratory tract, and/or gastrointestinal tract effective for treatment of a microorganism infection or a disorder of at least one tissue of the eye, respiratory tract, and/or gastrointestinal tract, wherein the pharmaceutical composition comprises 5′-adenosine diphosphate ribose (ADPR), or a pharmaceutically acceptable salt thereof, wherein the amount of ADPR, or a pharmaceutically acceptable salt thereof, is in the range of about 0.01% w/w to about 10% w/w of the pharmaceutical composition.